Abstract 262P
Background
There are 5,7 male and 3,8 female Non Hodgkin Lymphoma (NHL) patients per 100,000 populations in Indonesia. The expression of pPI3K/pAKT/pMTOR is an important expression in patients with NHL. Cascade signals from these biomarkers lead to translational regulation, cell survival, cytoskeleton organization, and ion transport. Lactate dehydrogenase (LDH) is an important marker in patients with NHL. pPI3K/pAKT/pMTOR increases gene transcription and encourages LDH proliferation.
Methods
An observational study by observing and measuring cancer cell samples from patients. Data collection method is cross sectional in which the independent and dependent variables are examined simultaneously. The expression values of pPI3K, pAKT, and pMTOR are expressed in form of histoscore. There are three range of intensity values which are one means weak, two means medium, and three mean strong, while the four distribution range are one means <20%, two means 20-50%, three means 50-80%, and four means >80%. Therefore the possible range of histoscore is from 1 to 12.
Results
The mean phosphorylated PI3K expression in NHL patients is 5,29 (2,95). The mean phosphorylated AKT expression in NHL patients is 4,71 (2,26). The mean expression of phosphorylated MTOR in NHL patients is 7,62 (1,86). The mean serum LDH level NHL patients is 428,57 (139,63) IU/L.
Conclusions
Correlation between the average expressions of pPI3K with the average level of serum LDH in NHL patients is relatively weak. The correlation between the mean of PAKT expression and the average level of LDH serum in NHL patients is classified as very weak. The correlation between mean pMTOR expression and mean serum LDH levels in NHL patients is very weak.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Andalas University, Padang.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
123P - The clinical value of prognostic nutritional index in esophagogastric junctional adenocarcinoma patients with anastomotic leakage after surgery
Presenter: Yan Wang
Session: e-Poster Display Session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session